World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
49054
World Ranking
8154
National Ranking
4228

Douglas B. Johnson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Douglas B. Johnson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 383 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Douglas B. Johnson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Douglas B. Johnson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Douglas B. Johnson is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily focuses on Medicine, with a specialization in Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine, and Epidemiology.

Their scientific contributions prominently cover key topics such as:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Colorectal Cancer Treatments and Studies
  • Brain Metastases and Treatment

Douglas B. Johnson has published extensively in well-known venues. The most frequent publication platforms include:

  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • European Journal of Cancer
  • Annals of Oncology
  • The Oncologist

Coauthorship is a significant aspect of their work, collaborating repeatedly with several researchers:

  • Georgina V. Long
  • Alexander M. Menzies
  • Matteo S. Carlino
  • Ryan J. Sullivan
  • Justin M. Balko

Recent papers authored or coauthored by them include:

  • Immune-checkpoint inhibitors: long-term implications of toxicity, 2022, Nature Reviews Clinical Oncology
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events, 2021, Journal for ImmunoTherapy of Cancer
  • Accuracy and Reliability of Chatbot Responses to Physician Questions, 2023, JAMA Network Open
  • Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study, 2020, Journal of the American Society of Nephrology
  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma, 2020, Cancer Cell

Best Publications

  • Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma

    Willy Hugo;Jesse M. Zaretsky;Lu Sun;Chunying Song

  • Fulminant Myocarditis with Combination Immune Checkpoint Blockade

    Douglas B. Johnson;Justin M. Balko;Margaret L. Compton;Spyridon Chalkias

  • Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

    Mark B. Faries;John F. Thompson;Alistair J. Cochran;Robert H. Andtbacka

  • Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

    Francesca Finotello;Clemens Mayer;Christina Plattner;Gerhard Laschober

  • Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

    Hubing Shi;Willy Hugo;Xiangju Kong;Aayoung Hong

  • Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

    Joe-Elie Salem;Joe-Elie Salem;Ali Manouchehri;Melissa Moey;Bénédicte Lebrun-Vignes

  • Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

    Satya Das;Douglas B. Johnson

  • Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

    Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson

  • Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

    Javid J. Moslehi;Joe Elie Salem;Jeffrey A. Sosman;Bénédicte Lebrun-Vignes

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak

  • Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis

    Steve Lu;Julie E. Stein;David L. Rimm;Daphne W. Wang

  • Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

    Willy Hugo;Hubing Shi;Lu Sun;Marco Piva

  • Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy

    Daniel Shae;Kyle W. Becker;Plamen Christov;Dong Soo Yun

  • Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Julie R. Brahmer;Hamzah Abu-Sbeih;Paolo Antonio Ascierto;Jill Brufsky

  • Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

    Douglas B. Johnson;Monica V. Estrada;Roberto Salgado;Violeta Sanchez

Frequent Co-Authors

Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Georgina V. Long
Georgina V. Long University of Sydney
Alexander M. Menzies
Alexander M. Menzies University of Sydney
Justin M. Balko
Justin M. Balko Vanderbilt University Medical Center
Ryan J. Sullivan
Ryan J. Sullivan Harvard University
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Javid Moslehi
Javid Moslehi University of California, San Francisco
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Keith T. Flaherty
Keith T. Flaherty Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The pathway to a medical career in the USA can be both rewarding and diverse. For those interested in advanced nursing roles, programs such as adn to fnp (Associate Degree in Nursing to Family Nurse Practitioner) offer a flexible route for working nurses to earn graduate-level credentials online.

Nutrition also plays a crucial role in healthcare. Earning a nutritionist online degree can open doors to positions in wellness, dietetics, and preventive care, empowering professionals to guide patients toward healthier lifestyles.

If you are seeking a leadership or administrative position in healthcare without pausing your career, discovering whats the best online mha program for working adults can help you gain managerial skills and industry credentials through recognized, flexible online programs.

In addition, options like rn to bsn programs without clinicals enable nurses to advance their education without the need for in-person clinicals, making it easier to grow professionally while maintaining work and life commitments.

Best Scientists Citing Douglas B. Johnson

Trending Scientists

Recently Published Articles